Meriva (Curcumin Phytosome)

Meriva is a patented phytosome complex combining curcumin with soy phospholipids (phosphatidylcholine) to dramatically enhance bioavailability. Each standard dose (typically 500 mg of Meriva complex) delivers approximately 100–120 mg of curcuminoids (curcumin, demethoxycurcumin, and bisdemethoxycurcumin) bound to 200–250 mg of phosphatidylcholine derived from soy lecithin, with the remainder being microcrystalline cellulose or other excipients. The phytosome formulation increases curcumin absorption approximately 29-fold compared to unformulated curcumin extract, as demonstrated in pharmacokinetic studies. Key bioactive compounds include curcumin (diferuloylmethane, the primary polyphenol, ~18–22% of the complex by weight), which is responsible for NF-κB inhibition, COX-2 suppression, and free radical scavenging (ORAC value of curcumin itself is exceptionally high, ~1,593,600 µmol TE/100g). Phosphatidylcholine (~40–50% of the complex) serves dual roles as both a bioavailability enhancer and a source of choline (~6–8 mg per dose), supporting hepatic lipid metabolism. Meriva is not a significant source of macronutrients (negligible calories, protein, fat, and carbohydrates per dose), nor does it provide meaningful amounts of vitamins or minerals. Peak plasma curcumin levels from Meriva reach approximately 50–80 ng/mL within 2–4 hours post-ingestion at a 1,000 mg dose (two capsules), compared to near-undetectable levels from equivalent doses of standard curcumin. The phospholipid matrix facilitates absorption through both lymphatic and portal pathways, improving distribution to target tissues including synovial fluid, liver, and plasma. Contains trace amounts of soy-derived isoflavones and residual solvent from processing. No significant fiber content.